Results 241 to 250 of about 14,877 (300)
Some of the next articles are maybe not open access.
T cell mediated allergy to abciximab
Allergy, 2002. A NONATOPIC woman, 54 years old, was referred for unstable angina. Coronary angiography revealed critical stenosis for which stenting was indicated, and which was performed under i.v. heparin and abciximab, infused for 12 h. Nine days later the patient underwent a generalized exanthemawith a cervicofacial swelling that persisted for several days.
J. M Vignaud +3 more
openaire +3 more sources
Abciximab: a review and update for clinicians
Expert Review of Cardiovascular Therapy, 2008The glycoprotein (GP) IIb/IIIa receptor serves as the final common pathway of platelet-thrombus formation. Thus, the GP IIb/IIIa receptor has been identified as a target for the prevention of thrombus formation during acute coronary syndromes and/or percutaneous coronary intervention. While there are several intravenous GP IIb/IIIa inhibitors available,
John J. Young, Ernest L. Mazzaferri
openaire +2 more sources
Abciximab and fatal pulmonary hemorrhage
Heart & Lung, 2006Abciximab, a platelet glycoprotein IIb/IIIa receptor blocker, is a well-known agent in percutaneous coronary intervention because of its antiplatelet, antithrombotic effects, which allow for good outcome. Major bleeding is a well-recognized complication of abciximab therapy, and pulmonary hemorrhage, although infrequent, is a serious, under-recognized,
Fahd Rahman +9 more
openaire +3 more sources
Comparison of eptifibatide and abciximab with decision analysis [PDF]
American Journal of Health-System Pharmacy, 2001 Dorothy H. Wong
openaire +4 more sources
Blood, 2002
Abstract Thrombocytopenia, often severe, occurs in 1% to 2% of patients given the fibrinogen receptor antagonist abciximab, a chimeric Fab fragment containing murine specificity-determining and human framework sequences. The cause of this complication has not yet been defined. Studies of 9 patients who developed profound thrombocytopenia
Richard H. Aster +4 more
openaire +3 more sources
Abstract Thrombocytopenia, often severe, occurs in 1% to 2% of patients given the fibrinogen receptor antagonist abciximab, a chimeric Fab fragment containing murine specificity-determining and human framework sequences. The cause of this complication has not yet been defined. Studies of 9 patients who developed profound thrombocytopenia
Richard H. Aster +4 more
openaire +3 more sources
Mortality in intracoronary versus intravenous abciximab
The Lancet, 2012www.thelancet.com Vol 380 July 7, 2012 25 UK (CEC, RST, JLC); Vascular Medicine, Peninsula NIHR Clinical Research Facility and Institute of Biomedical and Clinical Science, Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, UK (ACS); and Peninsula Collaboration for Leadership in Applied Health Research and Care (PenCLAHRC ...
Ankur Gupta, Yash Paul Sharma
openaire +6 more sources
Potential Anaphylactic Shock with Abciximab Readministration
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002A 46‐year‐old woman developed an anaphylactic reaction during percutaneous coronary intervention after she was pretreated with prednisone and diphenhydramine for a known allergy to iodine. She developed pruritus, edema, and nausea, which were followed by bradycardia and shock, minutes after administration of a bolus and standard‐dose infusion of ...
Donald A. Palisaitis +2 more
openaire +3 more sources
Delayed thrombocytopenia following abciximab therapy
International Journal of Cardiovascular Interventions, 2001Inhibitors of glycoprotein (GP) IIb/IIIa are currently approved for the treatment of acute coronary syndromes and during performance of percutaneous coronary interventions (PCIs). More than 500 000 patients annually undergo PCIs in the USA alone. Of these, 35% are receiving GPIIb/IIIa inhibitors.
Inna Khiger +3 more
openaire +3 more sources